A Pilot Study Evaluating the Efficacy of Regulatory T-cell (T-reg) Suppression by Denileukin Diftitox (Ontak) in Metastatic Pancreatic Cancer
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- T-reg Suppression From a Fractionated Dose of Ontak in Patients With Metastatic Pancreatic Cancer
研究概览
简要总结
This study is designed to determine the duration of T reg suppression in patients with metastatic pancreatic cancer receiving Ontak. The goal is to define the optimal time for future dendritic cell vaccine administration.
详细描述
Despite improved insight into the epidemiology and biology, pancreatic cancer remains a significant health problem as evidenced by the disappointing survival rates associated with advanced disease. Because of its aggressive growth and early metastatic dissemination, only 20% of patients can be treated by surgery at the time of diagnosis. Furthermore, the overall 5-year survival rate of stage IV disease is < 5% [1-3] despite chemotherapy. With such a dismal outlook, it is obvious that novel treatment strategies are required.
There is limited experience in the literature with the use of Ontak in the treatment of metastatic pancreatic cancer. Viehl, et al, demonstrated in a murine model of pancreatic cancer, that ontak combined with whole tumor vaccine led to a significantly increased T cell-dependent antitumor immune response, as well as an improved survival compared to controls. Our group has an active trial at Loyola evaluating the role of dendritic cell vaccine in patients with unresectable, not metastatic, pancreatic cancer. Preliminary data suggests a correlation with time to progression and restoration of Tregs following an initial decrease after the DC injection. The goal of the current proposal is to determine the time point at which the Tregs reach the nadir within four weeks of ontak injection. When this is determined, we will eventually propose administering ontak followed by DC vaccine at the nadir Treg time point for patients with unresectable pancreatic cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male patients and nonpregnant, nonlactating female patient > 18 years old
- •Histologic diagnosis of pancreatic cancer with distant disease seen on CT or MRI with no prior chemotherapy or radiotherapy for a least 4 weeks
- •Karnofsky performance status equal to or greater than 70%
- •Life expectancy of at least 3 months.
- •No uncontrolled pain
- •No symptoms of bowel obstruction
- •Women with child bearing potential must agree to use adequate contraceptives. If she should become pregnant she needs to inform the treating physician
- •Ability to give informed consent
排除标准
- •Positive serologic testing for HIV, AIDS, human T-cell lymphotrophic virus type 1, hepatitis B, or hepatitis C.
- •Hemoglobin <9g/dL; hematocrit <27%; platelets <100,000/ U/L without transfusion support
- •Creatinine > 1.8 mg/dL
- •Serum albumin < 2.0 mg/dL
- •AST > 3X ULN; ALT > 3X ULN
- •Bilirubin > 1.8
- •Uncontrolled angina, arrhythmias, bronchospasm, hypertension, or hypercalcemia.
- •Corticosteroid use within 28 days
- •Chemotherapy or radiation within 28 days
- •Bacteremia or other signs of active systemic infection
- •History of autoimmune disease
研究组 & 干预措施
1
Three doses of Ontak 9 mcg/Kg IV over 30 minutes every other day for 1 week
干预措施: Ontak (Drug)
结局指标
主要结局
T-reg Suppression From a Fractionated Dose of Ontak in Patients With Metastatic Pancreatic Cancer
时间窗: days 8, 12 ,19,26 and 33 post administration
The duration of T reg suppression from a fractionated dose of Ontak in patients will be measured in patients with metastatic pancreatic cancer.
次要结局
- Optimal Time for Future Dendritic Cell Vaccine Administration(33 Days)